secwatch.observer — SEC 8-K summary
======================================

Issuer:     eFFECTOR Therapeutics, Inc. (—)
CIK:        0001828522
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001193125-23-173792
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

eFFECTOR shareholders approve officer exculpation and reverse split authorization
--------------------------------------------------------------------------------

- Shareholders approved amendment to eliminate officer liability for monetary damages for breach of fiduciary duty.
- Shareholders authorized board to effect reverse stock split in range of 1:5 to 1:30 within one year.
- Re-elected three Class II directors: Gallagher, Ehrlich, Smither.
- Ratified Ernst & Young as independent auditor for fiscal year 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828522/000119312523173792/0001193125-23-173792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828522/000119312523173792/d464758d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-173792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer